Divergent Effects of D₂/₃ Receptor Activation in the Nucleus Accumbens Core and Shell on Impulsivity and Locomotor Activity in High and Low Impulsive Rats
Overview
Authors
Affiliations
Rationale: Previously we demonstrated reduced D2/3 receptor availability in the ventral striatum of hyper-impulsive rats on the five-choice serial reaction time task (5-CSRTT). However, the anatomical locus of D2/3 receptor dysfunction in high impulsive (HI) rats is unknown.
Objective: In the present study, we investigated whether D2/3 receptor dysfunction in HI rats is localised to the core or shell sub-regions of the nucleus accumbens (NAcb).
Methods: Rats were selected for low (low impulsive, LI) and high impulsivity on the 5-CSRTT and implanted with guide cannulae targeting the NAcb core and shell. The D2/3 receptor agonist quinpirole was locally injected in the NAcb (0.1, 0.3 and 1 μg per infusion) and its effects investigated on the performance of LI and HI rats on the 5-CSRTT as well as spontaneous locomotor activity in an open field.
Results: Intra-NAcb core quinpirole increased premature responding in HI rats but not in LI rats. In contrast, intra-NAcb shell quinpirole strongly increased locomotor activity in HI rats, unlike LI rats. This effect was blocked by intra-NAcb shell infusions of the D2/3 receptor antagonist nafadotride (0.03 μg). However, nafadotride was ineffective in blocking the effects of intra-NAcb core quinpirole on premature responding in HI rats.
Conclusions: These findings indicate that impulsivity and hyperactivity are separately regulated by core and shell sub-regions of the NAcb and that HI rats show an enhanced response to D2/3 receptor activation in these regions. These results suggest that the symptom clusters of hyperactivity and impulsivity in attention-deficit hyperactivity disorder may be neurally dissociable at the level of the NAcb.
Involvement of dopamine D3 receptor in impulsive choice decision-making in male rats.
Shen H, Ma Z, Hans E, Duan Y, Bi G, Chae Y Neuropharmacology. 2024; 257:110051.
PMID: 38917939 PMC: 11401648. DOI: 10.1016/j.neuropharm.2024.110051.
Laino Chiavegatti G, Floresco S Neurobiol Stress. 2024; 30:100633.
PMID: 38623397 PMC: 11016806. DOI: 10.1016/j.ynstr.2024.100633.
Magnard R, Fouyssac M, Vachez Y, Cheng Y, Dufourd T, Carcenac C Transl Psychiatry. 2024; 14(1):86.
PMID: 38336862 PMC: 10858232. DOI: 10.1038/s41398-024-02804-3.
Isaacson S, Hauser R, Pahwa R, Gray D, Duvvuri S Clin Park Relat Disord. 2023; 9:100212.
PMID: 37497384 PMC: 10366643. DOI: 10.1016/j.prdoa.2023.100212.
Fang Q, Frohlich F Neurosci Biobehav Rev. 2023; 152:105306.
PMID: 37419229 PMC: 10517644. DOI: 10.1016/j.neubiorev.2023.105306.